次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

パーキンソン病治療の世界市場:2022年に至る薬剤タイプ別、地域別予測

Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022

出版元:MarketsandMarketsLinkIcon出版元について
発行年:2017年 10月
定価 Single User License(1名様ライセンス)US$5,650(米国ドル)/Multi User License(5名様)$6,650 /Corporate User License $8,150
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email
当調査レポートは英文 115ページになります。
商品コード:MAM828

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
パーキンソン病治療の世界市場規模は2016年推計39億9000万ドルから、今後2022年には56億9000万ドル市場へと拡大が見込まれます。当レポートでは、2022年に至るパーキンソン病治療市場の世界市場予測(市場規模US$)、薬剤タイプ別市場(カルビドパ/レボドパ、ドーパミン受容体作動薬、モノアミン酸化酵素阻害薬、カテコール-O-メチル基転移酵素阻害薬、抗コリン作用薬、その他)、流通チャネル(病院薬局、調剤薬局、オンライン薬局)、患者ケア施設別市場(病院、クリニック)、主要国地域別市場など、詳細な市場予測データと分析を掲載しています。また市場分析、競合状況、主要メーカー企業13社プロフィール動向などの情報も交えて、パーキンソン病治療市場の現在と今後展開を予測分析していきます。

【レポート構成概要】pic04_pharma.jpg
◆ パーキンソン病治療の世界市場予測2015-2022年
・市場規模(US$)

◆ 薬剤タイプ別、市場-2022年
・カルビドパ/レボドパ
・ドーパミン受容体作動薬
・モノアミン酸化酵素阻害薬
・カテコール-O-メチル基転移酵素(COMT)阻害薬
・抗コリン作用薬
・その他
※(市場規模US$)

◆ 流通チャネル別、市場-2022年
・病院薬局
・調剤薬局
・オンライン薬局
※(市場規模US$)

◆ 患者ケア施設別、市場-2022年
・病院
・クリニック
※(市場規模US$)

◆主要国地域別市場-2022年
欧州
北米
・米国、カナダ
アジア
・日本、中国
・その他アジア
その他地域
※ 国、地域ごとに全セグメントの細分化データ掲載、詳細は目次参照

◆市場分析
・市場ダイナミクス(ドライバー、障壁、機会)

◆ パーキンソン病治療の主要企業プロフィール動向
・GSK
・MERCK
・NOVARTIS
・TEVA
・BOEHRINGER INGELHEIM
・IMPAX
・ABBVIE
・VALEANT PHARMACEUTICALS
・LUNDBECK
・SUN PHARMA
・WOCKHARDT
・ACADIA
・UCB

(全115頁)
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022

Table of Contents

1 INTRODUCTION 12

1.1 OBJECTIVES OF THE STUDY 12
1.2 MARKET DEFINITION 12
1.2.1 MARKETS COVERED 13
1.2.2 YEARS CONSIDERED FOR THE STUDY 13
1.3 CURRENCY 14
1.4 LIMITATIONS 14
1.5 STAKEHOLDERS 14

2 RESEARCH METHODOLOGY 15

2.1 RESEARCH DATA 16
2.1.1 SECONDARY DATA 16
2.1.1.1 Key data from secondary sources 16
2.1.2 PRIMARY DATA 17
2.1.2.1 Key data from primary sources 18
2.2 MARKET SIZE ESTIMATION 18
2.2.1 BOTTOM-UP APPROACH 19
2.2.2 TOP-DOWN APPROACH 20
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 21
2.4 ASSUMPTIONS FOR THE STUDY 22

3 EXECUTIVE SUMMARY 23
4 PREMIUM INSIGHTS 27

4.1 PARKINSON’S DISEASE TREATMENT MARKET OVERVIEW 27
4.2 GEOGRAPHIC ANALYSIS: PARKINSON’S DISEASE TREATMENT MARKET,
BY DRUG CLASS 28
4.3 GEOGRAPHIC ANALYSIS OF THE PARKINSON’S DISEASE TREATMENT MARKET,
BY COUNTRY 29
4.4 GEOGRAPHIC ANALYSIS OF THE PARKINSON’S DISEASE TREATMENT MARKET 30

5 MARKET OVERVIEW 31

5.1 INTRODUCTION 31
5.2 MARKET DYNAMICS 31
5.2.1 DRIVERS 32
5.2.1.1 Growth in aging population and the associated increase in the prevalence of Parkinson’s disease 32
5.2.1.2 Government funding for research 32
5.2.2 RESTRAINTS 33
5.2.2.1 Availability of alternative treatments 33
5.2.3 OPPORTUNITIES 34
5.2.3.1 Patent expiry of branded drugs 34
5.2.3.2 Strong drug pipeline 34

6 PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS 36

6.1 INTRODUCTION 37
6.2 CARBIDOPA/LEVODOPA 37
6.3 DOPAMINE RECEPTOR AGONISTS 39
6.4 MAO INHIBITORS 40
6.5 COMT INHIBITORS 42
6.6 ANTICHOLINERGICS 43
6.7 OTHER DRUGS 45

7 PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 47

7.1 INTRODUCTION 48
7.2 HOSPITAL PHARMACIES 49
7.3 RETAILER PHARMACIES 50
7.4 ONLINE PHARMACIES 51

8 PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING 52

8.1 INTRODUCTION 53
8.2 HOSPITALS 54
8.3 CLINICS 55

9 PARKINSON’S DISEASE TREATMENT MARKET, BY REGION 57

9.1 INTRODUCTION 58
9.2 EUROPE 59
9.3 NORTH AMERICA 61
9.3.1 U.S. 63
9.3.2 CANADA 65
9.4 ASIA 67
9.4.1 JAPAN 69
9.4.2 CHINA 71
9.4.3 REST OF ASIA 73
9.5 REST OF THE WORLD 75

10 COMPANY PROFILES 77

(Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*
10.1 GSK 77
10.2 MERCK 79
10.3 NOVARTIS 81
10.4 TEVA 83
10.5 BOEHRINGER INGELHEIM 86
10.6 IMPAX 88
10.7 ABBVIE 90
10.8 VALEANT PHARMACEUTICALS 92
10.9 LUNDBECK 94
10.10 SUN PHARMA 96
10.11 WOCKHARDT 98
10.12 ACADIA 100
10.13 UCB 102

*Details on MarketsandMarkets view, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments might not be captured in case of unlisted companies.
11 APPENDIX 105

LIST OF TABLES

TABLE 1 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET SUMMARY 23
TABLE 2 AGEING POPULATION, BY REGION, 2015 VS 2030 32
TABLE 3 PARKINSON’S DISEASE TREATMENT MARKET: LIST OF PIPELINE DRUGS 34
TABLE 4 PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS,
2016–2022 (USD MILLION) 37
TABLE 5 CARBIDOPA/LEVODOPA MARKET, BY REGION, 2015–2022 (USD MILLION) 38
TABLE 6 NORTH AMERICA: CARBIDOPA/LEVODOPA MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 38
TABLE 7 ASIA: CARBIDOPA/LEVODOPA MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 38
TABLE 8 DOPAMINE RECEPTOR AGONISTS MARKET, BY REGION,
2015–2022 (USD MILLION) 39
TABLE 9 NORTH AMERICA: DOPAMINE RECEPTOR AGONISTS MARKET,
BY COUNTRY, 2015–2022 (USD MILLION) 39
TABLE 10 ASIA: DOPAMINE RECEPTOR AGONISTS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 40
TABLE 11 MAO INHIBITORS MARKET, BY REGION, 2015–2022 (USD MILLION) 40
TABLE 12 NORTH AMERICA: MAO INHIBITORS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 41
TABLE 13 ASIA: MAO INHIBITORS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 41
TABLE 14 COMT INHIBITORS MARKET, BY REGION, 2015–2022 (USD MILLION) 42
TABLE 15 NORTH AMERICA: COMT INHIBITORS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 42
TABLE 16 ASIA: COMT INHIBITORS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 43
TABLE 17 ANTICHOLINERGICS MARKET, BY REGION, 2015–2022 (USD MILLION) 43
TABLE 18 NORTH AMERICA: ANTICHOLINERGICS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 44
TABLE 19 ASIA: ANTICHOLINERGICS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 44
TABLE 20 OTHER DRUGS MARKET, BY REGION, 2015–2022 (USD MILLION) 45
TABLE 21 NORTH AMERICA: OTHER DRUGS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 45
TABLE 22 ASIA: OTHER DRUGS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 46
TABLE 23 PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL,
2015–2022 (USD MILLION) 48
TABLE 24 PARKINSON’S DISEASE TREATMENT MARKET FOR HOSPITAL PHARMACIES,
BY REGION, 2015–2022 (USD MILLION) 49
TABLE 25 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2015–2022 (USD MILLION) 49
TABLE 26 PARKINSON’S DISEASE TREATMENT MARKET FOR RETAIL PHARMACIES,
BY REGION, 2015–2022 (USD MILLION) 50
TABLE 27 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET FOR RETAILER PHARMACIES, BY COUNTRY, 2015–2022 (USD MILLION) 50
TABLE 28 PARKINSON’S DISEASE TREATMENT MARKET FOR ONLINE PHARMACIES,
BY REGION, 2015–2022 (USD MILLION) 51
TABLE 29 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2015–2022 (USD MILLION) 51
TABLE 30 PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING,
2015–2022 (USD MILLION) 53
TABLE 31 PARKINSON’S DISEASE TREATMENT MARKET FOR HOSPITALS, BY REGION,
2015–2022 (USD MILLION) 54
TABLE 32 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2015–2022 (USD MILLION) 54
TABLE 33 ASIA: PARKINSON’S DISEASE TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2015–2022 (USD MILLION) 55
TABLE 34 PARKINSON’S DISEASE TREATMENT MARKET FOR CLINICS, BY REGION,
2015–2022 (USD MILLION) 55
TABLE 35 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET FOR CLINICS,
BY COUNTRY, 2015–2022 (USD MILLION) 56
TABLE 36 ASIA: PARKINSON’S DISEASE TREATMENT MARKET FOR CLINICS, BY COUNTRY, 2015–2022 (USD MILLION) 56
TABLE 37 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY REGION,
2015–2022 (USD MILLION) 58
TABLE 38 EUROPE: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS,
2015–2022 (USD MILLION) 59
TABLE 39 EUROPE: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION) 60
TABLE 40 EUROPE: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION) 60
TABLE 41 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET,
BY COUNTRY, 2015–2022 (USD MILLION) 62
TABLE 42 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET,
BY DRUG CLASS, 2015–2022 (USD MILLION) 62
TABLE 43 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET,
BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION) 62
TABLE 44 NORTH AMERICA: PARKINSON’S DISEASE TREATMENT MARKET,
BY PATIENT CARE SETTING, 2015–2022 (USD MILLION) 63
TABLE 45 US: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS,
2015–2022 (USD MILLION) 64
TABLE 46 US: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION) 64
TABLE 47 US: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION) 64
TABLE 48 CANADA: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS,
2015–2022 (USD MILLION) 65
TABLE 49 CANADA: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION) 66
TABLE 50 CANADA: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION) 66
TABLE 51 ASIA: PARKINSON’S DISEASE TREATMENT MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 68
TABLE 52 ASIA: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS,
2015–2022 (USD MILLION) 68
TABLE 53 ASIA: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION) 69
TABLE 54 ASIA: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION) 69
TABLE 55 JAPAN: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS,
2015–2022 (USD MILLION) 70
TABLE 56 JAPAN: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION) 70
TABLE 57 JAPAN: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION) 70
TABLE 58 CHINA: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS,
2015–2022 (USD MILLION) 71
TABLE 59 CHINA: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION) 72
TABLE 60 CHINA: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION) 72
TABLE 61 ROA: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS,
2015–2022 (USD MILLION) 73
TABLE 62 ROA: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION) 74
TABLE 63 ROA: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION) 74
TABLE 64 ROW: PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS,
2015–2022 (USD MILLION) 75
TABLE 65 ROW: PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015–2022 (USD MILLION) 75
TABLE 66 ROW: PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015–2022 (USD MILLION) 76

LIST OF FIGURES

FIGURE 1 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET 13
FIGURE 2 RESEARCH DESIGN 15
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 17
FIGURE 4 PARKINSON’S DISEASE TREATMENT MARKET: BOTTOM-UP APPROACH 19
FIGURE 5 PARKINSON’S DISEASE TREATMENT MARKET: TOP-DOWN APPROACH 20
FIGURE 6 DATA TRIANGULATION METHODOLOGY 21
FIGURE 7 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS,
2017 VS. 2022 24
FIGURE 8 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017 VS. 2022 24
FIGURE 9 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2017 VS. 2022 25
FIGURE 10 GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY REGION, 2017 VS. 2022 26
FIGURE 11 INCREASING PREVALENCE OF PARKINSON’S DISEASE TO DRIVE THE GROWTH OF THE PARKINSON’S DISEASE TREATMENT MARKET 27
FIGURE 12 CARBIDOPA/LEVODOPA SEGMENT AND JAPAN TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2017 28
FIGURE 13 JAPAN TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 29
FIGURE 14 EUROPE TO REGISTER THE HIGHEST MARKEST SHARE DURING THE FORECAST PERIOD 30
FIGURE 15 PARKINSON’S DISEASE TREATMENT MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 31
FIGURE 16 HOSPITAL PHARMACIES TO CONTINUE TO DOMINATE THE PARKINSON’S DISEASE TREATMENT MARKET DURING THE FORECAST PERIOD 48
FIGURE 17 HOSPITALS SEGMENT TO DOMINATE THE PARKINSON’S DISEASE TREATMENT MARKET DURING THE FORECAST PERIOD 53
FIGURE 18 PARKINSON’S DISEASE TREATMENT MARKET: GEOGRAPHIC SNAPSHOT
(2017-2022) 58
FIGURE 19 NORTH AMERICA: MARKET SNAPSHOT 61
FIGURE 20 ASIA: MARKET SNAPSHOT 67
FIGURE 21 GSK .: COMPANY SNAPSHOT 77
FIGURE 22 MERCK: COMPANY SNAPSHOT 79
FIGURE 23 NOVARTIS: COMPANY SNAPSHOT 81
FIGURE 24 TEVA : COMPANY SNAPSHOT 83
FIGURE 25 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT 86
FIGURE 26 IMPAX: COMPANY SNAPSHOT 88
FIGURE 27 ABBVIE.: COMPANY SNAPSHOT 90
FIGURE 28 VALEANT: COMPANY SNAPSHOT 92
FIGURE 29 LUNDBECK: COMPANY SNAPSHOT 94
FIGURE 30 SUN PHARMA: COMPANY SNAPSHOT 96
FIGURE 31 WOCKHARDT: COMPANY SNAPSHOT 98
FIGURE 32 ACADIA.: COMPANY SNAPSHOT 100
FIGURE 33 UCB: COMPANY SNAPSHOT 102

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。